perlecan


Also found in: Acronyms, Wikipedia.

perlecan

A heparin sulfate-rich proteoglycan (MW 600,000) located in the lamina densa of the basal lamina. It is associated with the structural organization and the filtering function of the basal lamina.
References in periodicals archive ?
Like endothelium, glomerular basement membrane is also considered to have charge- and size-selective properties because of its anionic heparan sulfate (HS) side chains attached to proteoglycan core proteins (e.g., agrin and perlecan) and extracellular matrix (ECM) network, respectively.
Sormunen et al., "Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney," TheEMBO Journal, vol.
Furthermore, a study on in vivo murine model demonstrated that SAA deposited in atherosclerotic areas at all stages of lesion development and highly correlated with lesion area, apo AI area, apoB-100 area, and perlecan area [42].
Dr Reddyes took the lead when it floated an integrated drug development research company Perlecan Pharma in FY06 by roping in Citigroup Venture Capital and ICICI Venture Capital.
Candidate polysaccharide or proteoglycan subunits include aggrecan, agrin, bamacan, heparan sulfate, chondroitin sulfate, keratan sulfate, versican, phosphocan, perlecan, hyaluronan, decorin, dermatan sulfate, biglycan, fibromodulin, alginate, polylactate, polyglycolic acid, starch, dextran, agarose, chitan, chitosan, and heparin.
Accumulation of Biglycan and Perlecan, but not Versican, in lesions of murine models of atherosclerosis.
Significantly, the new entity, Perlecan Pharma Private Limited (PPPL), also has the first right of refusal on the future pipeline of DRL at fair market price value.
Developmental expression of perlecan during murine embryogenesis.
Glucosamine sulfate (50 [micro]M) induced a two-fold increase in the steady levels of perlecan and aggrecan mRNA and caused a modest but consistent decrease in the levels of stromelysine mRNA.
On May 13, 2003, ProteoTech was issued United States Patent 6,563,016 entitled "Perlecan Transgenic Animals and Methods of Identifying Compounds for the Treatment of Amyloidoses." The patent is assigned to University of Washington and licensed exclusively to ProteoTech.
The distribution of structural proteins in body wall muscle cells including integins, perlecan, and M-lines will be assessed in the transgenic strains using epiflourescence and immunohistochemical analysis.
This molecule may act to stimulate the increased synthesis of the glycosaminoglycan known as perlecan, a basement membrane material.